ABSTRACT -Three female Crl:CD(SD) rats/group were dosed with single wall carbon nanotube (SWCNT) or multi wall carbon nanotube (MWCNT) four times by gavage at a total of 50 mg/kg bw or 200 mg/kg bw (four equally divided doses at one-hour intervals). Acute oral doses of SWCNT and MWCNT caused neither death nor toxicological effects, and thus the oral LD 50 values for SWCNT and MWCNT were considered to be greater than 50 mg/kg bw and 200 mg/kg bw, in rats respectively. Five or ten Crl:CD(SD) rats/sex were dosed with SWCNT once daily by gavage at a dose of 0 (control), 0.125, 1.25 or 12.5 mg/kg bw/day for 28 days with a 14-day recovery period (0 and 12.5 mg/kg bw/day groups). Six or twelve Crl:CD(SD) rats/sex were dosed with MWCNT once daily by gavage at a dose of 0 (control), 0.5, 5.0 or 50 mg/kg bw/day for 28 days with a 14-day recovery period (0 and 50 mg/kg bw/day groups). Based on no toxicological effects, the no observed adverse effect levels (NOAELs) of repeated dose toxicity of SWCNT and MWCNT were considered to be 12.5 mg/kg bw/day and 50 mg/kg bw/day (the highest dose tested), respectively. It was suggested that SWCNT and MWCNT dosed by gavage reached the gastro-intestinal tract as agglomerates and were mostly excreted via feces.
INTRODUCTION
Nanomaterials possess different physico-chemical properties from bulk materials. Therefore, it is necessary to develop specialized approaches to testing their effects on human health and on the environment. Our study group has worked on the establishment of a human health risk assessment methodology of nanomaterials since 2005. As part of efforts, our co-researchers reported carcinogenic potential of intraperitoneal administration of multi wall carbon nanotube (MWCNT) in p53 heterozygous mice (Takagi et al., 2008) and intrascrotal injection of MWCNT in intact Fischer 344 rats (Sakamoto et al., 2009) and also suggested that nano-sized particles can be transferred to other organs. Subsequently, Sakamoto et al. (2010) showed that expression of renal carcinoma/mesothelin can be used as a biomarker of mesothelial proliferative lesions induced by intrascrotal administration of MWCNT.
In parallel of the establishment of our study group, the OECD Working Party on Manufactured Nanomaterials (WPMN) was established to assess the safety of the use of nanomaterials for human health and the environment in 2006, and the Sponsorship Programme on the Testing on Manufactured Nanomaterials was launched in 2007 (OECD, 2011) . The aim of the Sponsorship Programme is to fill data gaps between existing data and a desired data set for 13 nanomaterials including single wall carbon nanotubes (SWCNTs) and MWCNTs. Japan has volunteered to act as the Joint Lead Sponsors with the US for the evaluation of mammalian toxicology for fullerenes (C60), SWCNTs and MWCNTs in the Sponsorship Programme. We recently reported no toxicological effects of gavage doses of fullerene C60 up to 1,000 mg/kg bw/ day in rats (Takahashi et al., 2012) . After the 29-day administration period, blackish feces and black contents of the stomach and large intestine were observed. Fullerene C60 was not detected in the liver, spleen or kidney at the end of administration period. This study indicated that fullerene C60 dosed by gavage was excreted via feces and not distributed in major organs.
We also conducted acute and repeated dose toxicity studies of SWCNT and MWCNT by gavage, target endpoints of the Sponsorship Programme. In some past studies, the physical-chemical properties of tested materials are not clear due to the diversity of carbon nanotubes (CNTs) with respect to purity, production methods, purification methods or surface treatments/ coatings (Kobayashi et al., 2009; OECD, 2011) . The clear characterization and good control of the size and shape of nano-sized particulate materials are essential for ensuring the reproducibility and reliability of tests. Therefore, well defined Nikkiso SWCNT and MWCNT were set as principal samples in this Sponsorship Programme to examine mammalian toxicity.
Major current uses of MWCNTs are electronics applications such as super-capacitors and batteries and structural composite applications such as sporting equipments and conductive sheets (OECD, 2010a) and the future applications of MWCNTs include medical care and fabrics (Kobayashi et al., 2009; MHLW, 2010) . Major expecting uses of SWCNTs in future are super-capacitors, high speed transistor, fuel cells, super high strength wires (OECD, 2010b) . A total volume of production and import of MWCNTs was 500 tons in 2008 in Japan, and it is expected to increase in future (MHLW 2010) . Oral exposure to CNTs may occur through the migration from food contact products or agricultural foods that uptake CNTs from environment (Magnuson et al., 2011) .
Many toxicity studies have been available for SWCNTs or MWCNTs dosed by pharyngeal aspiration (Erdely et al., 2009; Shvedova et al., 2008) , intravenous injection (Yang et al., 2008) , intratracheal instillation (Inoue et al., 2009; Elgrabli et al., 2008; Inoue et al., 2008) and inhalation (Shvedova et al., 2008) in rats and mice, but this will be the first report to show the results of acute and repeated dose toxicity of SWCNT and MWCNT by gavage in rats according to the OECD guidelines (TG 423 and TG 407) . Although a gavage dose is not likely to be representative of the anticipated exposure scenario, the findings of our studies will be useful to characterize the feature of CNTs toxicity and for risk assessment in humans. (June 1, 2006) . The MWCNT studies were conducted in compliance with the Guidelines for Animal Experimentation (May 22, 1987) , along with the above described Acts and Standards. and the basic morphology is particles consisting of entangled MWCNTs with a diameter of around 30 nm. Both test materials were not coated or modifi ed. The test materials were stored in a polycarbonate bottle with an airtight stopper to prevent dissemination at room temperature, and were accurately weighed and added to gum acacia (vehicle). This vehicle was chosen based on the results of the preliminary investigation with commonly used vehicles, in which CNTs showed the best dispersion state in 5% gum acacia of aqueous solution. The mixture of test materials was homogenized using an ultrasonic homogenizer (SWCNT: UR-200P, TOMY Seiko Co., Ltd., Tokyo, Japan; MWCNT: VC-130, Sonics & Materials Inc., Newtown, CT, USA) and a compact ultrasonic cleaning bath (SWCNT: US-1, As One Co., Ltd., Tokyo, Japan; MWCNT: USC-6, Iwaki Glass Co., Ltd., Chiba, Japan). The homogeneity of test suspensions was confirmed microscopically (Figs. 1 and 2).
MATERIALS AND METHODS

Acute
Acute toxicity studies for SWCNT and MWCNT were conducted in a stepwise procedure. As a fi rst step, three female rats/group were dosed with SWCNT or MWCNT four times by gavage at a total of 50 mg/kg bw or 200 mg/kg bw (four equally divided doses at one-hour intervals), respectively. Because oral toxicity of the test materials was expected to be low, dosage levels were determined based on the maximum doses which could be prepared and administered. The concentrations of 0.625 mg/ml SWCNT and 2.5 mg/ml MWCNT were confi rmed to be the limit to prepare. In addition, ethically, a dosing volume of 20 ml/kg was limit for gavage dosing and four times seemed to be the limit for the number of dosing times. In the fi rst step, no deaths or adverse effects were found for either SWCNT or MWCNT dosing. Therefore, a second step was carried out with the same regimen to confi rm the acute toxicity of the test materials.
Five or ten rats/sex were dosed with SWCNT once daily by gavage at a dose of 0 (control), 0.125, 1.25 or 12.5 mg/kg bw/day for 28 days. Five animals/sex at 0 and 12.5 mg/kg bw/day were used as the recovery groups and were observed for 14 days after the administration period. Six or twelve rats/sex were dosed with MWCNT once daily by gavage at a dose of 0 (control), 0.5, 5.0 or 50 mg/kg bw/day for 28 days. Six animals/sex at 0 and 50 mg/kg bw/day were used as the recovery groups and were observed for 14 days after the administration period. A high dose was set with the maximum doses which could be prepared, as described above, and the middle and low doses were set with a common ratio of 10.
Observations
As for the acute toxicity studies, rats were observed for 14 days. Clinical observation was performed consecutively for several hours after administration and once or twice a day from the next day of administration. Animals were weighed just prior to administration, and 1, 3, 5, 7, 10 and 14 days (MWCNT) or 1, 3, 7 and 14 days (SWCNT) after administration. Necropsy was performed 14 days after administration.
As for the repeated dose studies, all males and females in the MWCNT study were observed twice per day, every day during administration and recovery periods, and in the SWCNT were observed three times per day, every day during the administration and once a day during the recovery period. A detailed clinical observation was carried out one day before administration, on days 7, 14, 21 and 28 days of the administration period and days 7 and 14 of the recovery period in the MWCNT study, and once a week in the SWCNT study. A functional examination was carried out in the fourth week of the administration period and in the second week of the recovery period. Body weight was measured on days 1, 4, 7, 14, 21 and 28 of the administration period and on days 7 and 14 of the recovery period in the MWCNT study, and on days 1, 4, 7, 10, 14, 17, 21, 24 and 28 of the administration period and on days 1, 3, 7, 10 and 14 of the recovery period. Food consumption was measured on days 1, 7, 14, 21 and 28 of the administration period, and on days 7 and 14 of the recovery period. Hematological examinations were performed on blood samples obtained from fasted rats just prior to necropsy. Clinical chemistry examinations were performed on blood samples obtained from fasted rats just prior to necropsy. Necropsy was performed under anesthesia on the day following the end of the administration or recovery period. The external surfaces of rats were examined and a gross internal examination was performed. Organ weights were measured and histopathological evaluations were performed on the organs. Urinary samples were collected for 3 or 4, and 20 hr in the fourth week of the administration period, and in the second week of the recovery period. Urine volume was calculated and a urinary examination was conducted.
Data analysis
For the SWCNT study, continuous data from the administration period were analyzed by the Bartlett test for homogeneity of distribution. When homogeneity was recognized, data were analyzed by the Dunnett test, whereas heterogeneous data were analyzed by the Dunnett-type mean rank test between the control group and individual treatment groups. For the recovery group data, homogeneity of variance was tested by the F-test. When homogeneity was recognized, the difference in mean values between the control group and treatment groups was analyzed by a Student's t-test, whereas heterogeneous data were analyzed by an Aspin-Welch's t-test.
For the MWCNT study, continuous data were analyzed by the Bartlett test for homogeneity of distribution. When homogeneity was recognized, the Dunnett test was conducted for comparison between the control group and individual treatment groups after a one-way layout analysis of variance. If not homogenous, the data were analyzed using the Kruskal-Wallis test followed by a MannWhitney's U-test. Qualitative data were analyzed by the Kruskal-Wallis test followed by Mann-Whitney's U-test.
RESULTS AND DISCUSSION
Acute oral doses of SWCNT and MWCNT caused neither death nor toxicological effects on the clinical observation and body weight. Thus, the oral LD 50 values for SWCNT and MWCNT were considered to be greater than 50 mg/kg bw and 200 mg/kg bw in rats, respectively (data not shown).
A 28-day dose of SWCNT caused no death in both sexes. There were no differences in the clinical observation, detailed clinical observation, body weight and food consumption (Table 1) or histopathological examination (Table 2 ). In the functional examination, significantly low values of landing foot splay were observed in all the treatment groups in males at the end of the administration period (90 ± 11, 61 ± 15, 64 ± 18 and 75 ± 10 mm at 0, 0.125, 1.25 and 12.5 mg/kg bw/day, respectively). However, it was due to the high value in the control group and was not considered to be toxicological effects. In urinalysis, a significantly low urine volume was observed during the administration period in females at 1.25 mg/kg bw/day and above (Table 3) . However, these values were within the historical background data of the test facility (Mean ± S.D.: 8.3 ± 4.0 ml/24 hr), and these were not dose dependent. In the hematological examination, significantly high erythrocyte counts in females and lymphocyte counts and basophil counts in males were observed at 12.5 mg/kg bw/day at the end of the administration period (Table 4) . However, these changes were considered to be incidental because there were no changes in related parameters. In the serum biochemistry examination, significantly high alanine aminotransferase and triglyceride levels were observed in females in the 0.125 mg/kg bw/day group but not in the high dose groups at 
Lymphoid hyperplasia ++ 1 --0 0 --0 Grade; +: slight change; ++: mild change, -: Not applicable (a) :The histopathological examination was carried out in 5 animals at 0 and 12.5 mg/kg bw/day and the kidney was examined in 5 females at 0.125 and 12.5 mg/kg bw/day. 15.3 ± 3.6 12.8 ± 4.5 8.1 ± 1.5 5.5 ± 2.3** 8.1 ± 3.1* Osmolality (mOsm/kg) 1696 ± 407 1710 ± 455 1459 ± 208 1758 ± 352 1874 ± 507 2046 ± 239 2296 ± 463 2104 ± 394 *: Significantly different from the control group (p < 0.05). **: Significantly different from the control group (p < 0.01). 15.5 ± 0.6 15.6 ± 0.4 15.7 ± 0.6 15.2 ± 1.6 15.4 ± 0.7 15.9 ± 0.4 15.9 ± 0.4 16.2 ± 0.7 Hematocrit (%) 45.7 ± 1.4 45.5 ± 1.3 46 ± 1.8 44.8 ± 4.7 43.6 ± 2.3 45.5 ± 1 45.4 ± 1.1 46.3 ± 1.9 MCV (fl) 54.3 ± 1.3 53.8 ± 0.9 56.1 ± 1 54.9 ± 2 53.9 ± 2.5 54.1 ± 1.2 52.9 ± 0.9 53.9 ± 1.3 MCH (pg)
18.5 ± 0. 19 ± 2 34 ± 10** 27 ± 10 22 ± 1 LDH (IU/l) 54 ± 8 53 ± 7 52 ± 5 54 ± 6 52 ± 3 63 ± 16 57 ± 12 56 ± 9 γ-GTP (IU/l) 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 1 1 ± 0 1 ± 0 ALP (IU/l) 647 ± 198 686 ± 82 655 ± 73 663 ± 84 415 ± 127 359 ± 102 378 ± 34 470 ± 102 T. bile acid (μmol/l) 15.1 ± 12.7 12.5 ± 4.9 10.5 ± 7.5 7.6 ± 2.9 12.2 ± 2.3 15.4 ± 4.9 11.3 ± 3.1 11.6 ± 6.3 T. cholesterol (mg/dl) 50 ± 5 48 ± 14 52 ± 7 50 ± 6 55 ± 7 57 ± 14 66 ± 16 50 ± 17 Triglyceride (mg/dl) 56 ± 19 55 ± 22 50 ± 18 59 ± 24 14 ± 3 29 ± 12* 21 ± 11 14 ± 6 Phospholipid (mg/dl) 93 ± 8 92 ± 14 94 ± 10 93 ± 10 100 ± 11 108 ± 18 123 ± 20 95 ± 26 T. bilirubin (mg/dl) 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 0.1 ± 0 Glucose (mg/dl) 126 ± 13 121 ± 5 135 ± 18 141 ± 12 113 ± 11 106 ± 11 122 ± 8 123 ± 23 BUN (mg/dl) 13 ± 2 14 ± 3 12 ± 1 14 ± 2 16 ± 2 16 ± 2 15 ± 2 16 ± 2 Creatinine (mg/dl) 0.24 ± 0.02 0.24 ± 0.02 0.25 ± 0.02 0.25 ± 0.03 0.27 ± 0.02 0.26 ± 0.04 0.27 ± 0.02 0.28 ± 0.01 Sodium (mmol/l) 144 ± 1 144 ± 1 144 ± 1 143 ± 1 144 ± 1 143 ± 1 143 ± 1 143 ± 2 Potassium (mmol/l) 4.6 ± 0.1 4.6 ± 0.1 4.6 ± 0.1 4.7 ± 0.2 4.3 ± 0.2 4.4 ± 0.3 4.2 ± 0.2 4.2 ± 0.2 Chloride (mmol/l) 105 ± 1 106 ± 1 105 ± 1 106 ± 1 107 ± 1 107 ± 1 107 ± 2 107 ± 1 Calcium (mg/dl) 10 ± 0.2 9.8 ± 0.2 10.2 ± 0.3 9.8 ± 0.2 10 ± 0.3 10 ± 0.1 9.9 ± 0.1 10 ± 0.1 I. phosphorus (mg/dl) 7.8 ± 0.3 7.5 ± 0.4 7.9 ± 0.5 7.5 ± 0.6 7 ± 0.3 7 ± 0.6 6.9 ± 0.9 6.9 ± 0.8 T. protein (g/dl)
5.8 ± 0.1 6 ± 0.1 6 ± 0.1 5.9 ± 0.2 6.4 ± 0.3 6.2 ± 0 6.2 ± 0.2 6.1 ± 0.1 Albumin (g/dl)
3.2 ± 0 3.2 ± 0.1 3.2 ± 0.1 3.2 ± 0.1 3.6 ± 0.2 3.5 ± 0.1 3.6 ± 0.1 3.5 ± 0.1 Albumin/Globlin 1.21 ± 0.09 1.14 ± 0.07 1.15 ± 0.08 1.23 ± 0.06 1.31 ± 0.12 1.31 ± 0.09 1.43 ± 0.08 1.35 ± 0.07 AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; LDH: lactate dehydrogenase; ALP: Alkaline phosphatase; BUN: Blood urea nitrogen Vol. 37 No. 3 the end of the administration period (Table 5 ). In organ weight measurements, a significantly low absolute weight of the spleen was observed in males in the 12.5 mg/kg group at the end of the administration period (Table 6) . However, there were no changes in the relative weight and histopathological examination of the spleen. A significantly high relative weight of the heart was observed in females in the 0.125 mg/kg group but not in the high dose groups at the end of the administration period. At necropsy, a dark red focus in the lung was observed sporadically in the control group and 12.5 mg/kg bw/day group at the end of the administration and recovery periods. At the histopathological examination, focal hemorrhage in the lung was observed in the animals showed a dark red focus. Blackish contents were observed in the cecum of animals in the treatment groups at the end of administration period. However, the histopathological examination revealed no effects in these organs. The contents in the intestines were not observed after the recovery period. Significant differences noted at the end of administration period all disappeared by the end of the recovery period.
A 28-day dose of MWCNT caused no death in both sexes. Black feces were observed in both sexes in all the treatment groups. No effects were found on detailed clinical observation, functional examination, body weight and food consumption (Table 7) , organ weights, urinalysis and histopathology (Table 8 ). In the hematological examination, eosinophil counts were significantly low in females in the 5.0 and 50 mg/kg bw/day groups at the end of the administration period (Table 9 ) and in the 50 mg/ bw/day group at the end of recovery period (1.13 ± 0.38 × 10 2 /μl vs. 0.73 ± 0.23 × 10 2 /μl), but the changes were within the historical background data of the test facility (0.9 ± 0.86 × 10 2 /μl). A few female animals incidentally showed high values for eosinophils in the control group, and a significant decrease in eosinophil counts was considered to be due to the high value of eosinophils in the control group. Therefore, it was not considered to be clinically (b) 12.3 ± 1.5 11.3 ± 2 11.7 ± 1.2 10.6 ± 0.6 14.9 ± 1.1 12.5 ± 2 12.6 ± 1.9 13.2 ± 2.4 (mg%) (c) 3 ± 0.3 3.1 ± 0.5 3 ± 0.4 2.8 ± 0.2 6.4 ± 0.4 5.5 ± 0.7 6 ± 0.9 5.8 ± 0.7 Thyroid (mg) 21.9 ± 4.8 18 ± 2.4 20.2 ± 2.8 17.6 ± 2.1 14.2 ± 0.8 15.2 ± 2.5 13.2 ± 2.5 14.5 ± 1.7 (mg%) 5.4 ± 0.9 4.9 ± 0.6 5.2 ± 0.7 4.7 ± 0.4 6.1 ± 0.5 6.7 ± 1 6.3 ± 1. 87.4 ± 8.6 84.9 ± 4.5 81.3 ± 12.3 91.9 ± 11.6 (mg%) 37.7 ± 4.1 37.4 ± 1.6 38.5 ± 5.5 41.1 ± 6.7 Uterus (mg) 470 ± 143 334 ± 52 460 ± 107 407 ± 84 (mg%) 202 ± 56 148 ± 25 218 ± 45 180 ± 30 *: Significantly different from the control group (p < 0.05). Vol. 37 No. 3 or toxicologically important. Table 10 shows the results of serum biochemistry in rats dosed MWCNT. A significantly low γ-globulin fraction in females in the 50 mg/ kg group was not accompanied by significant differences in other fractions, and no changes were noted in related parameters such as white blood cell counts. This was also considered to be due to a high value in the control group. Gamma-GTP in males in the 0.5 mg/kg group was significantly lower than that in the control group, but it was not dose-dependent. These changes in serum biochemistry were not observed at the end of the recovery period. Necropsy at the end of the administration period revealed swelling of the submandibular lymph node in one male in the 0.5 mg/kg group. This change was not dose-dependent and was not considered to be toxicologically important. Grayish green/dark green contents in the cecum, colon and/or rectum were observed in both sexes at 5.0 mg/kg bw/day and higher. These contents in the intes- 212.9 ± 13.3 213.2 ± 10.9 215.5 ± 14.0 215.0 ± 10.9 161.7 ± 9.9 161.8 ± 9.4 160.8 ± 10.7 159.1 ± 10.8 Day 7
242.0 ± 15.0 242.0 ± 14.4 244.5 ± 13.8 241.5 ± 13.0 172.0 ± 11.9 172.7 ± 15.4 172.0 ± 15.9 168.7 ± 13.3 Day 14 305.7 ± 18.5 304. Calcium (mg/dl) tines were not observed after the recovery period. Based on the absence of toxicological effects, the no observed adverse effect levels (NOAELs) of repeated dose toxicity of SWCNT and MWCNT were considered to be 12.5 mg/ kg bw/day and 50 mg/kg bw/day in rats (the highest dose tested), respectively. Our findings showed no toxicological effects of orally administered CNTs, but available data show CNTs, under some conditions, may induce harmful effects. Both SWCNTs and MWCNTs showed the capacity to induce toxicity such as inflammation and fibrosis in the lung when administered by pharyngeal aspiration, intratracheal instillation or inhalation (Shvedova et al., 2008; Erdely et al., 2009; Inoue et al., 2008; Pauluhn, 2010; Warheit et al., 2004; Lam et al., 2004; Han et al., 2008) . The carcinogenic potential of intraperitoneally administered MWCNT was observed in p53 heterozygous mice (Takagi et al., 2008) and intrascrotal injection of MWCNT in intact Fischer 344 rats (Sakamoto et al., 2009) . The cytotoxic potential of CNTs was also observed in skin and lung cells in vitro (Jia et al., 2005; MonteiroRiviere et al., 2005) although cytotoxicity can be influenced by various factors such as material impurities, length and size distribution, surface area, and so on (Hussain et al., 2009) . Intravenously injected CNTs increased oxidative stress markers in the lung and liver in mice (Yang et al., 2008) or induced slight hepatotoxicity by inflammation and oxidative damage in mice (Ji et al., 2009) . Deng et al. (2007) showed that intratracheally dosed taurine-functionalized MWCNT accumulated mainly in the lung and remained there until 28 days following administration whereas an oral gavage dose led to distribution in the small/large intestines and stomach, and about 74% was excreted in the feces after 12 hr. Intravenously injected taurine-functionalized MWCNT accumulated and remained until 28 days following administration in the liver, lung and spleen. The authors of this study suggested that taurine-functionalized-MWCNT cannot enter the blood circulation or be absorbed by the intestine tracts, and that routes of exposure influence the distribution of CNTs although the distribution pattern was for functionalized MWCNT. The findings of a study by Deng et al. (2007) together with our study suggested that SWCNTs and MWCNTs dosed by gavage reached the gastrointestinal tract as agglomerates and were rapidly excreted via feces in rats.
However, there is a study in which rats were dosed with SWCNT by gavage once at 0.64 mg/kg bw, and the levels of oxidatively damaged DNA increased in the liver and lung tissue (Folkmann et al., 2009) . Furthermore, significant increases in the number of resorptions, and fetal morphological and skeletal abnormalities, were observed in fetuses of CD-1 mouse dams that were administered functionalized CNTs by gavage at 10 mg/kg bw/day on day 9 of gestation (Philbrook et al., 2011) . Surface functionalization increases solubility of CNTs, and therefore absorbability of CNTs could have been increased in this study. However, these two studies suggested that CNTs could be absorbed from the gastro-intestinal tract into the blood circulation.
The findings of a study by Philbrook et al. (2011) are in discord from a study by Lim et al. (2011) , in which pregnant SD rats were given MWCNTs by gavage at 0-1,000 mg/kg bw/day on days 6-19 of gestation, and no adverse effects were found in fetuses. Although controversial findings were observed in oral dose studies, an intravenous study obviously showed the teratogenic potential of CNTs (Pietroiusti et al., 2011) . Pregnant CD-1 mice were intravenously injected with SWCNT, oxidized-SWCNT and ultra oxidized-SWCNT at 0-30 μg/ animal on day 5.5 of gestation. Increases in incidence of early miscarriages and fetal malformations were observed in all treatment groups at 0.1 μg/animal and higher. This study suggested that low-dose SWCNTs may induce fetal malformations. Our study group will undertake further teratogenic studies to confirm whether CNTs cause developmental toxicity.
In conclusion, rats were dosed with SWCNT or MWCNT once daily by gavage for 28 days with a 14-day recovery period, and no toxicological effects were found up to the highest dose tested. However, the possibility that CNTs dosed by oral administration are absorbed from the gastro-intestinal tract and persistent in the body for the long term cannot be ruled out, and a further study for chronic oral toxicity will be helpful to confirm the safety of CNTs. Because of the small size of CNTs, particles may spread over the entire body, and causing adverse effects like observed in intravenous studies, once absorbed.
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